These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 21029028

  • 21. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis.
    Salmanpour R, Razmavar MR, Abtahi N.
    Int J Dermatol; 2006 Sep; 45(9):1115-6. PubMed ID: 16961529
    [No Abstract] [Full Text] [Related]

  • 22. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG.
    J Infect Dis; 2006 May 15; 193(10):1375-83. PubMed ID: 16619185
    [Abstract] [Full Text] [Related]

  • 23. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R, Handjani F, Nouhpisheh MK.
    J Dermatolog Treat; 2001 Sep 15; 12(3):159-62. PubMed ID: 12243707
    [Abstract] [Full Text] [Related]

  • 24. Treatment of kala-azar in India.
    Thakur CP.
    Natl Med J India; 1992 Sep 15; 5(5):203-5. PubMed ID: 1338871
    [No Abstract] [Full Text] [Related]

  • 25. Low dose glucantime therapy in Leishmania viannia braziliensis (Lvb) infections.
    Costa JM, Marsden PD.
    Rev Soc Bras Med Trop; 1988 Sep 15; 21(2):85-6. PubMed ID: 3249826
    [No Abstract] [Full Text] [Related]

  • 26. Leishmaniasis.
    Evans TG.
    Infect Dis Clin North Am; 1993 Sep 15; 7(3):527-46. PubMed ID: 8254158
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T.
    Am J Trop Med Hyg; 2007 Jul 15; 77(1):99-101. PubMed ID: 17620637
    [Abstract] [Full Text] [Related]

  • 28. Retention of antimony in hair during leishmaniasis treatment.
    Dorea JG, Merchan-Hamann E, Ryan DE, Holzbecher J.
    Clin Chim Acta; 1989 Feb 22; 179(3):341-5. PubMed ID: 2714007
    [No Abstract] [Full Text] [Related]

  • 29. [Intralesional treatment of cutaneous leishmaniasis: a report of two cases].
    Clarós P, Wienberg P, González MA, Clarós A, Clavería MA, López P.
    Acta Otorrinolaringol Esp; 1996 Feb 22; 47(1):67-70. PubMed ID: 8645493
    [Abstract] [Full Text] [Related]

  • 30. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD.
    Am J Trop Med Hyg; 2005 Feb 22; 72(2):133-7. PubMed ID: 15741547
    [Abstract] [Full Text] [Related]

  • 31. Leishmania amazonensis: effects of oral treatment with copaiba oil in mice.
    dos Santos AO, Costa MA, Ueda-Nakamura T, Dias-Filho BP, da Veiga-Júnior VF, de Souza Lima MM, Nakamura CV.
    Exp Parasitol; 2011 Oct 22; 129(2):145-51. PubMed ID: 21771592
    [Abstract] [Full Text] [Related]

  • 32. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis.
    Yébenes M, Cruz I, Cañavate C, Gilaberte M, Baena V, Pujol RM.
    Clin Exp Dermatol; 2008 Mar 22; 33(2):142-4. PubMed ID: 18076691
    [Abstract] [Full Text] [Related]

  • 33. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, Dedet JP, Campino L, Cañavate C, Dujardin JC.
    Trop Med Int Health; 2008 Oct 22; 13(10):1272-6. PubMed ID: 18764817
    [Abstract] [Full Text] [Related]

  • 34. The chemotherapy of protozoal infections: whither?
    Steck EA.
    J Protozool; 1981 Feb 22; 28(1):30-5. PubMed ID: 6265632
    [No Abstract] [Full Text] [Related]

  • 35. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
    Yardley V, Ortuno N, Llanos-Cuentas A, Chappuis F, Doncker SD, Ramirez L, Croft S, Arevalo J, Adaui V, Bermudez H, Decuypere S, Dujardin JC.
    J Infect Dis; 2006 Oct 15; 194(8):1168-75. PubMed ID: 16991093
    [Abstract] [Full Text] [Related]

  • 36. [Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].
    Henao HH, Osorio Y, Saravia NG, Gómez A, Travi B.
    Biomedica; 2004 Dec 15; 24(4):393-402. PubMed ID: 15678803
    [Abstract] [Full Text] [Related]

  • 37. Recent advances in the treatment of visceral leishmaniasis.
    Davidson RN, Croft SL.
    Trans R Soc Trop Med Hyg; 1993 Dec 15; 87(2):130-1, 141. PubMed ID: 8393221
    [No Abstract] [Full Text] [Related]

  • 38. [Postkala-azar dermal leishmaniasis].
    de Juan Martín F, Justa Roldán ML, Sáez de Adana Pérez E, Navarro Serrano E, Bouthelier Moreno M, Gilaberte Calzada Y, Fortuño Cebamanos B.
    An Esp Pediatr; 1997 Jan 15; 46(1):63-4. PubMed ID: 9082890
    [No Abstract] [Full Text] [Related]

  • 39. Pentavalent antimonials: new perspectives for old drugs.
    Frézard F, Demicheli C, Ribeiro RR.
    Molecules; 2009 Jun 30; 14(7):2317-36. PubMed ID: 19633606
    [Abstract] [Full Text] [Related]

  • 40. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
    Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C.
    Pathol Biol (Paris); 1997 Jun 30; 45(6):496-9. PubMed ID: 9309267
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.